Aptevo Therapeutics Inc (NASDAQ:APVO) has been given a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.

Brokers have set a 12-month consensus price objective of $11.50 for the company and are forecasting that the company will post ($0.59) EPS for the current quarter, according to Zacks. Zacks has also given Aptevo Therapeutics an industry rank of 92 out of 255 based on the ratings given to related companies.

A number of research firms have recently weighed in on APVO. Zacks Investment Research upgraded shares of Aptevo Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a research note on Tuesday, August 14th. ValuEngine upgraded shares of Aptevo Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, August 13th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $11.00 price objective on shares of Aptevo Therapeutics in a research note on Friday, August 10th.

Large investors have recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Aptevo Therapeutics in the second quarter worth $148,000. Citadel Advisors LLC boosted its holdings in Aptevo Therapeutics by 215.4% during the first quarter. Citadel Advisors LLC now owns 39,653 shares of the biotechnology company’s stock worth $130,000 after buying an additional 27,079 shares in the last quarter. EAM Investors LLC purchased a new stake in Aptevo Therapeutics during the second quarter worth $552,000. Spark Investment Management LLC boosted its holdings in Aptevo Therapeutics by 82.8% during the first quarter. Spark Investment Management LLC now owns 129,400 shares of the biotechnology company’s stock worth $423,000 after buying an additional 58,600 shares in the last quarter. Finally, Park West Asset Management LLC purchased a new stake in Aptevo Therapeutics during the first quarter worth $604,000. Hedge funds and other institutional investors own 33.08% of the company’s stock.

Aptevo Therapeutics stock traded down $0.05 during mid-day trading on Thursday, reaching $5.05. 452 shares of the company traded hands, compared to its average volume of 89,408. The company has a current ratio of 3.66, a quick ratio of 3.50 and a debt-to-equity ratio of 0.27. Aptevo Therapeutics has a fifty-two week low of $1.71 and a fifty-two week high of $6.35. The firm has a market capitalization of $115.84 million, a price-to-earnings ratio of -3.30 and a beta of 0.68.

Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.58) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.07. The firm had revenue of $6.83 million for the quarter, compared to analyst estimates of $4.17 million. Aptevo Therapeutics had a net margin of 74.01% and a negative return on equity of 45.53%. sell-side analysts predict that Aptevo Therapeutics will post -2.41 EPS for the current fiscal year.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.

Read More: Average Daily Trade Volume Explained

Get a free copy of the Zacks research report on Aptevo Therapeutics (APVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.